FDA approves GSK's Arnuity Ellipta

LONDON — GlaxoSmithKline announced FDA approval for Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid medicine for the treatment of asthma in patients 12 years of age and older.



"The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio. It is the first asthma treatment from our new portfolio to have gained approval in the US and enables us to begin expanding the range of medicines that we offer to physicians and appropriate patients," said Darrell Baker, SVP and head, GSK global respiratory franchise.



The approved dosage strengths are 100 mcg and 200 mcg. Arnuity is delivered by the dry powder inhaler Ellipta, which is also used across a range of respiratory medications in GSK's portfolio.